Somapacitan is Effective and Well Tolerated in Chinese Children with Growth Hormone Deficiency: a Randomised Controlled Phase 3 Study
Efficacy and safety profiles were comparable for Chinese children with GHD treated with somapacitan or daily GH. Both treatments similarly reduced disease burden, while treatment burden was reduced with somapacitan.
Authors
- Tina Lund Leunbach (ORCID: https://orcid.org/0000-0001-7996-7596)
- Yining Zhang (ORCID: https://orcid.org/0000-0003-1367-5325)
- Michael Højby Rasmussen (ORCID: https://orcid.org/0000-0002-2210-0366)
- Junfen Fu (ORCID: https://orcid.org/0000-0001-6405-1251)
- Chunxiu Gong (ORCID: https://orcid.org/0000-0002-1262-7383)
- Haiyan Wei (ORCID: https://orcid.org/0000-0003-1044-6594)
- Yan Zhong (ORCID: https://orcid.org/0000-0003-1132-5567)
- Yanhong Li (ORCID: https://orcid.org/0000-0002-5449-729X)
- Limin Zhu (ORCID: https://orcid.org/0000-0003-3194-6731)
- Xinran Cheng (ORCID: https://orcid.org/0009-0009-4781-8778)
Institutions
- Sun Yat-sen University (CN)
- Novo Nordisk (Denmark) (DK)
- Jilin University (CN)
- Zhengzhou University (CN)
- Chengdu Women's and Children's Central Hospital (CN)
- Novo Nordisk (Switzerland) (CH)
- Zhengzhou Children's Hospital (CN)
- Children's Hospital of Zhejiang University (CN)
- First Hospital of Jilin University (CN)
- Changchun Children's Hospital (CN)
- The First Affiliated Hospital, Sun Yat-sen University (CN)
- Hunan Children's Hospital (CN)
- Beijing Children’s Hospital (CN)
Publication Details
- Journal
- Hormone Research in Paediatrics
- Published
- 2025-05-05
- DOI
- https://doi.org/10.1159/000545786
- Citations
- 6
- Primary Topic
- Growth Hormone and Insulin-like Growth Factors
- Type
- article
- Field-Weighted Citation Impact
- 7.77
Funders
- Novo Nordisk